Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa

About this episode

The episode features Dr. Luciano Costa discussing the MajesTEC-3 trial and the implications of bispecific therapies in myeloma treatment.

Join hosts Raj, Ashwin, and Eddie in this episode of Blood Cancer Talks as they welcome Dr. Luciano Costa, the first author of the NEJM manuscript on the MajesTEC-3 RCT, which was presented at ASH 2025. This episode dives deep into the trial's topline findings, capturing the nuances of the patient population, efficacy and safety data, and the future implications for treatment. The episode also examines the comparative efficacy of bispecific T-cell engagers versus CAR-T therapies, along with spirited discussion on the potential for fixed-duration treatment in myeloma care. Episode Highlights Main Topics Covered MajesTEC-3 Trial: Teclistamab-Daratumumab vs. Standard of Care Trial design and patient population Primary endpoint: Progression-free survival (PFS) MRD negativity rates and depth of response Overall survival and safety profile Clinical implications for treatment selection Treatment Selection in Early Relapse Comparing MajesTEC-3 and CARTITUDE-4 patient populations Framework for choosing between bispecific antibodies vs. CAR T-cell therapy Managing anti-CD38 exposed patients Link to the NEJM paper: https://www.nejm.org/doi/abs/10.1056/NEJMoa2514663

People in this episode

Hosts: Rajshekhar Chakraborty, Ashwin Kishtagari, Edward Cliff

Guest: Dr. Luciano Costa

Topics covered

• MajesTEC-3 Trial
• myeloma treatment
• bispecific therapies
• CAR-T therapies
• clinical implications
• patient population

Keywords

• MajesTEC-3
• myeloma
• Teclistamab-Daratumumab
• CAR-T
• bispecific T-cell engagers
• clinical trial
• efficacy
• safety
• treatment selection

Mentioned in this episode

Organizations: NEJM

Products: Teclistamab-Daratumumab, CAR-T therapies, bispecific T-cell engagers

More episodes of Blood Cancer Talks

• Episode 71. Management of Newly Diagnosed Multiple Myeloma with Dr. Vincent Rajkumar · May 19, 2026 · 52 min
• Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez · February 27, 2026 · 57 min
• Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo · January 22, 2026 · 44 min
• Episode 67. Management of CMV in Hematologic Malignancies · November 23, 2025 · 40 min
• Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza · October 15, 2025 · 52 min
• Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain · September 24, 2025 · 53 min